雪榕生物(300511) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥440,692,931.37, a decrease of 27.04% compared to ¥603,985,503.43 in the same period last year[5] - Total operating revenue decreased to ¥440,692,931.37 from ¥603,985,503.43, representing a decline of approximately 27%[22] - Total operating costs decreased to ¥440,694,795.18 from ¥602,081,762.76, a reduction of about 27%[22] - Net profit for the period increased to ¥12,248,024.25 compared to ¥10,702,846.50, showing an increase of approximately 14%[23] - Net profit attributable to shareholders increased by 38.20% to ¥7,242,399.82 from ¥5,240,339.19 year-on-year[5] Cash Flow and Liquidity - The net cash flow from operating activities rose by 8.12% to ¥86,083,523.69 compared to ¥79,620,418.03 in the previous year[5] - Operating cash inflow for the current period was $437,465,747.80, a decrease of 30% from $625,262,991.86 in the previous period[25] - Net cash flow from operating activities increased to $86,083,523.69, up from $79,620,418.03, representing a growth of 5.8%[25] - Cash outflow from investing activities was $21,139,903.61, significantly lower than $225,133,378.38 in the previous period, indicating a reduction of 90.6%[25] - Net cash flow from investing activities improved to -$14,803,661.38 from -$211,239,268.15, showing a positive change of 93%[25] - Cash inflow from financing activities totaled $147,590,000.00, down 82.8% from $859,525,881.17 in the previous period[26] - Net cash flow from financing activities was -$176,816,188.35, a decline from $622,031,168.28, reflecting a decrease of 128.4%[26] - The ending cash and cash equivalents balance decreased to $44,392,997.38 from $647,061,490.68, a drop of 93.2%[26] - The company's cash and cash equivalents decreased from 167,953,803.72 yuan to 44,780,056.33 yuan, a decline of approximately 73.3%[19] Assets and Liabilities - Total assets decreased by 4.50% to ¥3,681,036,326.42 from ¥3,854,555,536.98 at the end of the previous year[5] - The total assets decreased to ¥3,681,036,326.42 from ¥3,854,555,536.98, a decline of about 4.5%[21] - Total liabilities decreased significantly, with a notable drop in contract liabilities by 73.29% to ¥5,508,558.48 from ¥20,620,117.76[8] - Total liabilities decreased to ¥2,609,403,210.59 from ¥3,031,232,610.38, a reduction of approximately 13.9%[21] - The total non-current assets decreased from 3,000,000,000 yuan to approximately 2,900,000,000 yuan, reflecting a decline of about 3.3%[19] Shareholder Information - The total number of common shareholders at the end of the reporting period is 35,338[13] - The largest shareholder, Yang Yongping, holds 19.53% of the shares, totaling 107,606,850 shares[13] - The total number of restricted shares held by Yang Yongping remains at 80,705,137 shares due to executive lock-up regulations[15] - The company has not disclosed any other related party relationships among shareholders[14] Research and Development - Research and development expenses decreased by 66.68% to ¥505,920.27 from ¥1,518,369.89 year-on-year[9] - Research and development expenses decreased to ¥505,920.27 from ¥1,518,369.89, a decline of approximately 67%[22] Other Income and Comprehensive Income - The company recorded a 39.17% increase in other income, amounting to ¥3,450,029.09 compared to ¥2,479,024.48 in the same period last year[9] - The company reported a comprehensive income total of ¥12,186,978.16, slightly up from ¥12,125,088.65, indicating stable performance[23] Corporate Actions - The company signed a framework agreement for a change of control with Shanghai Wanzihong Intelligent Technology Co., Ltd., which will result in a change of the controlling shareholder[16] - The company plans to issue new shares to specific investors as part of the control change agreement[16] Accounting Standards - The company did not execute any new accounting standards adjustments for the current reporting period[27]